Socio-economic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany - Socio-economical aspects in hepatitis C;Sozio-ökonomische charakteristika, lebensqualität und wissensstand bei patienten mit hepatitis-C-virusinfektion in deutschland: Sozio-ökonomische aspekte bei hepatitis C

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 4, 2006, Pages 305-317

  Niederau, Claus ^a,c   Bemba, G ^b   Kautz, A ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Deutsche Leberhilfe eV   (Germany)

^c St Josef Hospital Oberhausen   (Germany)

Author keywords

Hepatitis C virus; Interferon; Liver biopsy; Liver cirrhosis; Quality of life; Repairing

Indexed keywords

VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EDUCATION; FIBROSIS; GERMANY; HEALTH INSURANCE; HEPATITIS C; HUMAN; INSURANCE; INTERNET; MAJOR CLINICAL STUDY; PENSIONER; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIOECONOMICS; VIRUS TRANSMISSION;

ADULT; FEMALE; GERMANY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; MALE; PATIENTS; QUALITY OF LIFE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 33646544756     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926510     Document Type: Article

References (84)

1. www.who.org
2. www.cdc.org
3. www.rki.de
4. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62-65
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52
6. Davis GL, Balart LA, Schiff ER et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334-343
7. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV: Results of HQL. Dig Dis Sci 1996; 41: 75-80
8. Lee DH, Regenstein FG. Morbidity of chronic hepatitis C as seen in a tertiary medical center. Dig Dis Sci 1997; 42: 186-191
9. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C infection causes a significant reduction in HRQOL in the absence of cirrhosis. Hepatology 1998; 27: 209-212
10. Sladden TJ, Hickey AR, Dunn TM et al. Hepatitis C virus infection: impacts on behaviour and lifestyle. Aust N Z J Public Health 1998; 22: 509-511
11. Neary MP, Cort S, Bayliss MS et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19: 77-85
12. Ware JE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999; 30: 550-555
13. Davis GL, Balert LA, Schiff ER et al. Assessing health-related Quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334-343
14. Bayliss MS, Gandek B, Bungay KM et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 39-55
15. Bonkovsky HL, Woolley JM and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-270
16. Rodger AL, Jolley D, Thompson SC et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-1301
17. McHutchison JG, Ware JE jr, Bayliss MS et al. The effects of interferon alpha-2 b in combination with ribavirin on health related quality of life and work productivity. Hepatology 2001; 34: 140-147
18. Bernstein D, Kleinman L, Barker CM et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-708
19. Fontana RJ, Hussain KB, Schwartz SM et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Hepatology 2002;36:401-407
20. Gallegos-Orozco JF, Fuentes AP, Argueta JG et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003; 34: 124-129
21. Wright M, Forton D, Main J et al. (on behalf of the UK Mild HCV Trial investigators). Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005; 12: 58-66
22. Kraus MR, Schäfer A, Csef H et al. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 377-384
23. Häuser W, Zimmer C, Schiedermaier P et al. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004; 66: 954-958
24. www.kompetenznetz-hepatitis.de
25. Bullinger M, Kirchberger I. SF36-Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe Verlag, 1998
26. Hays RD, Cunningham WE, Sherbourne CD et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108: 714-722
27. Remy AJ, Daures JP, Tanguy G et al. Measurement of the quality of life in chronic hepatitis C: validation of a general index and specific index. Gastroenterol Clin Biol 1999; 23: 1296-1309
28. Juenger J, Schellberg D, Kraemer S et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002; 87: 235-241
29. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 2001; 32: 413-417
30. Dalgard O, Egeland A, Skaug K et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39: 74-80
31. Wenger NK. Quality of life issues in hypertension: consequences of diagnosis and considerations in management. Am Heart J 1988; 116: 628-632
32. Park CK, Park SY, Kim ES et al. Assessment of quality of life and associated factors in patients with chronic viral liver disease. Taehan Kan Hakhoe Chi 2003; 9: 212-221
33. Cordoba J, Flavia M, Jacas C et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231-238
34. Chong CA, Gulamhussein A, Heathcote EJ et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-638
35. Goh J, Coughlan B, Quinn J et al. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833-838
36. Dwight MM, Kowdley KV, Russo JE et al. Depression, fatigue and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311-317
37. Hussain KB, Fontana RJ, Moyer CA et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2734-2744
38. Zickmund S, Ho EY, Masuda M et al. "They treated me like a leper". Stigmatization and the quality of life of patients with chronic hepatitis C J Gen Intern Med 2003; 18: 835-844
39. Sherman KE, Sherman SN, Chenier T et al. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164: 2377-2382
40. Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001; 25: 355-361
41. Hogg RS, Craib KJ, Pi D et al. Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990. Can J Public Health 2003; 94: 130-134
42. Hassoun Z, Willems B, Deslauriers J et al. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002; 47: 2674-2681
43. Glacken M, Coates V, Kernohan G et al. The experience of fatigue for people living with hepatitis C. J Clin Nurs 2003; 12: 244-252
44. Filippini D, Colombo F, Jann S et al. Central nervous system involvement in patients with HCV-related cryoglobulinemia: literature review and a case report. Reumatismo 2002; 54: 150-155
45. Dawson TM, Starkebaum G. Isolated central nervous system vasculitis associated with hepatitis C infection. J Rheumatol 1999; 26: 2273-2276
46. Origgi L, Vanoli M, Carbone A et al. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998; 315: 208-210
47. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440-446
48. Kramer L, Bauer E, Funk G et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 3: 349-354
49. Forton DM, Thomas HC, Murphy CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439
50. Hilsabeck RC, Hassanein TI, Carlson MD et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847-854
51. Weissenborn K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851
52. Morsica G, Bernardi MT, Novati R et al. Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 1997; 5: 252-254
53. Vargas HE, Laskus T, Radkowski M et al. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl 2002; 8: 1014-1019
54. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 81-86
55. Singh N, Gayowski T, Wagener MM et al. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67: 69-72
56. Dickson RC, Wright RM, Bacchetta MD et al. Quality of life of hepatitis B and C patients after liver transplantation. Clin Transplant 1997; 11: 282-285
57. Bianchi G, Loguercio C, Sgarbi D et al. Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Dig Liver Dis 2000; 32: 398-405
58. Zidlar D, Franco-Bronson K, Buchler N et al. Hepatitis C, Interferon Alfa, and depression. Hepatology 2000; 31: 1207-1211
59. Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related interferon-alpha induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90
60. Bonaccorso S, Marino V, Biondi M et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Aff Dis 2002; 72: 237-241
61. Kraus MR, Schäfer A, Faller H et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2 b therapy. J Clin Psychiatry 2003; 6: 708-714
62. Gohier B, Goeb JL, Rannou-Dubas K et al. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003; 4: 115-118
63. Horiwaka N, Yamazaki T, Izumi N et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospectie study. Gen Hosp Psychiaty 2003;25:34-38
64. Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2 a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681
65. Kraus MR, Schäfer A, Wißmann S et al. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2 b and ribavirin. Clin Pharmacol Ther 2005; 77: 90-100
66. Dieperink E, Ho SB, Thuras P et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-112
67. Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha 2 b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2 b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432
68. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
69. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
70. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
71. Hadziyannis SJ, Sette HJr, Morgan TR et al. PEGASYS International Study Group.Peginterferon-alpha2 a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
72. Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2 a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732
73. Kalyoncu OA, Tan D, Mirsal H et al. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005; 19: 102-105
74. Schäfer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-451
75. Marcellin P, Lau GK, Bonino F et al. Peginterferon Alfa-2 a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2 a alone, lamivudine alone, and the two in combination in patients with HBe-Ag-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
76. Janssen HL, van Zonneveld M, Senturk H et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2 b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129
77. Van Thiel DH, Friedlander L, Molloy PJ et al. Interferon alpha can be used successfully in patients with Hepatitis C virus positiv chronic hepatitis hwo have a psychiatric illness. Eur J Gastroent Hepatol 1995; 7: 165-168
78. Malaguarnera M, Di Fazio I, Restuccia S et al. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-97
79. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19: 67-75
80. Gohier B, Goeb JL, Rannou-Dubas K et al. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003; 4: 115-118
81. Horiwaka N, Yamazaki T, Izumi N et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospectie study. Gen Hosp Psychiatry 2003; 25: 34-38
82. Tanaka Y, Nagaki M, Tomita E et al. Psychoneurological symptoms during interferon therapy in patients with chronic hepatitis: prospective study on predictive use of Cornell Medical Index and electroencephalogram. Liver Int 2004; 24: 407-412
83. Desmorat H, Combis JM, Pradat P. Assessment of quality of life in chronic hepatitis C: [effect of treatment]. Gastroenterol Clin Biol 2003; 27: 1084-1090
84. Coughlan B, Sheehan J, Hickey A et al. Psychological well-being and quality of life in women with an iatrogenic hepatitis C virus infection. Br J Health Psychol 2002; 7: 105-116